云南白药 reported revenue of ¥21.88B for the period ended 2026-06-30, +2.9% year on year. Net income was ¥3.70B, a 16.9% net margin on a 30.1% gross margin. The largest revenue line is 批发零售 at 60% of the total. Free cash flow for the period was ¥3.19B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥21.88B | +2.9% |
| Gross profit | ¥6.58B | — |
| Operating income | ¥4.27B | — |
| Net income | ¥3.70B | +1.4% |
| Gross margin | 30.1% | Net margin 16.9% |
| Revenue Q/Q | -11.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 批发零售 | ¥13.06B | 59.7% |
| 工业产品(自制) | ¥8.77B | 40.1% |
| 其他(补充) | ¥0.04B | 0.2% |
| 其他服务 | ¥0.01B | 0.1% |
| 农产品 | ¥0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥15.31B | 69.9% |
| R&D | ¥0.19B | 0.9% |
| SG&A | ¥2.78B | 12.7% |
| Tax & other | ¥0.58B | 2.6% |
| Item | Amount |
|---|---|
| Total assets | ¥55.15B |
| Total liabilities | ¥14.10B |
| Shareholders' equity | ¥41.05B |
| Equity / assets | 74.4% |
| Operating cash flow | ¥3.28B |
| Capital expenditure | ¥0.09B |
| Free cash flow | ¥3.19B |
| Cash conversion (OCF / net income) | 111% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
泸州老窖 ・ 古井贡酒 ・ 中油资本 ・ 长安汽车 ・ 铜陵有色 ・ 格力电器 ・ 中钨高新 ・ 中信特钢 ・ 京东方A ・ 中航西飞 ・ 广发证券 ・ 盐湖股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies